Study Completed

Prevention of venous thromboembolism after MOS

Bayer Identifier:

14022

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2009-014379-39

EU CT Number:

Not Available

BAY59-7939, Characterization of oral solution

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 - 55 Years

Trial summary

Enrollment Goal

Trial Dates

September 2009 - December 2009

Phase

Phase 1

Could I Receive a placebo

N/A

Products

Xarelto (Rivaroxaban, BAY59-7939)

Accepts Healthy Volunteer

N/A

Where to participate

Status	Institution	Location
Completed	Bayer HealthCare	Wuppertal, 42096, Germany

Trial design

Single-dose, open-label, randomized, 4-way crossover study to compare 10 and 20 mg of an oral suspension of rivaroxaban under fasting and 20 mg of an oral suspension of rivaroxaban under fed conditions to 10 mg of an immediate release tablet under fasting conditions in healthy subjects

Trial Type

Interventional

Intervention Type

N/A

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.